The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Open accessAbstract
BACKGROUND: Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio. METHODS: Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for a median of 6.5 months were randomly assigned to placebo or low-intensity warfarin (target INR, 1.5 to 2.0). Participants were followed for recurrent venous thromboembolism, major hemorrhage, and death. RESULTS: The trial was terminated early after 508 patients had undergone randomization and had been followed for up to 4.3 years (mean, 2.1). Of 253 patients assigned to placebo, 37 had recurrent venous thromboembolism (7.2 per 100 person-years), as compared with 14 of 255 patients assigned to low-intensity warfarin (2.6 per 100 person-years), a risk reduction of 64 percent (hazard ratio, 0.36 [95 percent confidence interval, 0.19 to 0.67]; P<0.001). Risk reductions were similar for all subgroups, including those with and those without inherited thrombophilia. Major hemorrhage occurred in two patients assigned to placebo and five assigned to low-intensity warfarin (P=0.25). Eight patients in the placebo group and four in the group assigned to low-intensity warfarin died (P=0.26). Low-intensity warfarin was thus associated with a 48 percent reduction in the composite end point of recurrent venous thromboembolism, major hemorrhage, or death. According to per-protocol and as-treated analyses, the reduction in the risk of recurrent venous thromboembolism was between 76 and 81 percent. CONCLUSIONS: Long-term, low-intensity warfarin therapy is a highly effective method of preventing recurrent venous thromboembolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Furthermore, trials in that analysis were published before 2004, whereas since then additional prospective studies have reported on the risk for recurrent VTE after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, with several of these studies having followed patients beyond 24 months and some up to 10 years.9 10 11 12 13”
From Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis (2019) · cites this paper as [9]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,769
Poort, S., Rosendaal, F. R., Reitsma, P. H., & Bertina, R. M. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,045
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,094
Resistance to Activated Protein C as a Basis for Venous Thrombosis
Svensson, P. J., & Dahlbäck, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402243300801 · Cited by 1,127
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057
Ridker, P. M., Hennekens, C. H., Lindpaintner, K., Stampfer, M. J., Eisenberg, P. R., & Miletich, J. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321403 · Cited by 1,031
Self-citationSchulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous Catheters
Bern, M. M., Lokich, J. J., Wallach, S. R., Bothe, A., Benotti, P. N., Arkin, C. F., Greco, F. A., Huberman, M., & Moore, C. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-423 · Cited by 787
Flagged first, then by citations
Research works printed but not linked: 2
- Kearon C, 2002, Blood, 100, 150a
- Eriksson H, 2002, Blood, 100, 81a
Cited by
Sorted by citations
Items 401–500 of 807
Pourafkari, L., Baghbani‐Oskouei, A., Savadi, S., Ghaffari, S., Parizad, R., Tajlil, A., & Nader, N. D. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00774-9 · Cited by 10
Anticoagulation in pulmonary arterial hypertension: a decision analysis
Jose, A., Eckman, M. H., & Elwing, J. (2019) · Pulmonary Circulation · doi:10.1177/2045894019895451 · Cited by 10
“37.(30,31,39) We made the simplifying assumption that systemic AC protected equally from both central catheterrelated DVT as well as DVT from other causes, and was equally protective across gender and etiology of PAH (CTD-PAH versus IPAH), and the rates of DVT across gender, use of OCP’s in women, and presence of cent…”
BackgroundRipley, T. L., Havrda, D. E., Blevins, S. M., & Culkin, D. J. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.16.1638.50949 · Cited by 10
Ximelagatran for the secondary prevention of venous thromboembolism
Schulman, S., Lundström, T., Wåhlander, K., Clason, S. B., Eriksson, H., & for the THRIVE III Investigators (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-04-0228 · Cited by 10
Stopping anticoagulant therapy after an unprovoked venous thromboembolism
Kearon, C. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.081080 · Cited by 10
A new indication for statins to prevent venous thromboembolism? Not yet
Cushman, M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03282.x · Cited by 11
Self-citationManagement of venous thromboembolism for older adults in long‐term care facilities
Choi, M., & Hector, M. G. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00733.x · Cited by 10
Goldhaber, S. Z., Nadel, E. S., King, M. E., & Sharma, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmcpc049008 · Cited by 10
Self-citationLeitlinienverfahrens, M. D., Leitlinienkoordination: Prof. Dr. med. Viola Hach-Wunderle, F. A. M., AWMF: Priv.-Doz. Dr. med. Ina Kopp, M., Leitliniensteuerung: Dr. med. W. Blättler, D. M. H. G., Redaktion: Dr. med. W. Blättler, D. M. H. G., Redaktion: Dr. med. W. Blättler, D. M. H. G., Dt. Ges. für Chirurgie (DGCh) Prof. Dr. med. A. Encke, F. A. M., Dt. Ges. für Gefäßchirurgie (DGG) Dr. med. Th. Noppeney, N. P.-D. D. M. A. S., Dt. Ges. für Gynäkologie und Geburtshilfe (DGGG) Prof. Dr. med. M.W. Beckmann, E., Dt. Ges. für Hämatologie und Onkologie (DGHO) Prof. Dr. med. H. Riess, B., et al. (2006) · Intensivmedizin und Notfallmedizin · doi:10.1007/s00390-006-0618-0 · Cited by 10
Warfarin: balancing the benefits and harms
Borosak, M. (2004) · Australian Prescriber · doi:10.18773/austprescr.2004.074 · Cited by 10
Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases
Yetkin, U., Karabay, Ö., & Önol, H. (2004) · Current Controlled Trials in Cardiovascular Medicine · doi:10.1186/1468-6708-5-1 · Cited by 10
Willenberg, T., Banyai, M., Frank, U., Baldi, T., Amann-Vesti, B. R., Baumgärtner, I., Spirk, D., Husmann, M. J. W., & Kucher, N. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-08-0506 · Cited by 10
Evidence-based management of thrombosis in the antiphospholipid antibody syndrome
Petri, M. (2003) · Current Rheumatology Reports · doi:10.1007/s11926-003-0023-7 · Cited by 11
Venous Thromboembolism Guidebook
Gelfand, E. V., Piazza, G., & Goldhaber, S. Z. (2002) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/00132577-200203000-00006 · Cited by 10
Self-citationTreatment of ANCA-Associated Vasculitis
Santana, A. N. C., Antunes, T., & Barbas, C. S. V. (2007) · JAMA · doi:10.1001/jama.298.23.2739-a · Cited by 10
Establishing an Optimal Therapeutic Range for Coumarins
O'Donnell, M. J., & Hirsh, J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.6.588 · Cited by 10
Anticoagulation and compression therapy for proximal acute deep vein thrombosis
Palareti, G., Santagata, D., Ponti, C. D., Ageno, W., & Prandoni, P. (2024) · VASA · doi:10.1024/0301-1526/a001138 · Cited by 9
Imberti, D., Pomero, F., & Mastroiacovo, D. (2020) · Blood transfusion · doi:10.2450/2019.0265-18 · Cited by 10
Venous thromboembolism in centenarians: Findings from the RIETE registry
Lacruz, B., Tiberio, G., Núñez, M. J., López‐Jiménez, L., Riera‐Mestre, A., Tiraferri, E., Verhamme, P. B., Mazzolai, L., González, J., & Monréal, M. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.07.025 · Cited by 9
Management of venous thromboembolism
de Moerloose, P., Samama, C. M., & Motte, S. (2006) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03022255 · Cited by 9
Isolated Calf Vein Thrombosis Should Be Treated With Anticoagulation
Lohr, J. M., & Fellner, A. N. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2010.06.010 · Cited by 9
Novel Antiplatelet and Anticoagulant Agents in the Cardiac Care Unit
Garg, V., & Halperin, J. L. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.07.001 · Cited by 9
Long-term Management of Venous Thromboembolism
Bauer, K. A. (2011) · JAMA · doi:10.1001/jama.2011.361 · Cited by 9
Self-citationThe Role of Ximelagatran in the Treatment of Venous Thromboembolism
Schulman, S. (2005) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000083080 · Cited by 9
“This regimen has been evaluated in the Prevention of REcurrent VENous Thromboembolism (PRE-VENT) trial, in which patients with idiopathic VTE who had been receiving conventional-intensity warfarin for a median of 6.5 months were randomized to receive either low-intensity warfarin or placebo for long-term (4.3 years) s…”
MethodInfluentialSullivan, L. T., Jackson, L. R., & Thomas, K. L. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1352-5 · Cited by 10
Fox, K. A. A., White, H. D., Gersh, B. J., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00018-1 · Cited by 9
Thromboses veineuses des membres inférieurs et de la veine cave inférieure
Léger, P., Barcat, D., Boccalon, C., Guilloux, J., & Boccalon, H. (2004) · EMC - Cardiologie-Angéiologie · doi:10.1016/j.emcaa.2003.11.002 · Cited by 9
Treatment of Cancer-Associated Thrombosis: Distinguishing Among Antithrombotic Agents
Pruemer, J. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.01.021 · Cited by 9
Is the current classification of venous thromboembolism acceptable? No
WHITE, H., & Murin, S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.01075.x · Cited by 9
Diagnostic methods in pulmonary embolism
Nijkeuter, M., & Huisman, M. V. (2005) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2005.01.008 · Cited by 9
“0 has been associated with an annual incidence of major bleeding ranging from 5% to 9% [5].”
BackgroundRecognizing and managing deep vein thrombosis
DAY, M. W. (2003) · Nursing · doi:10.1097/00152193-200305000-00044 · Cited by 9
Goldhaber, S. Z. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00012 · Cited by 9
“For now, I believe that results from the PREVENT (Prevention of Recurrent Venous Thromboembolism) trial should guide us (5).”
Self-citationBoureka, E., Arvanitaki, A., Ralli, E.-E., Lefkou, E. E., Fragakis, N., Giannakoulas, G. A., Eskitzis, P., Mamopoulos, A. M., Dagklis, T., & Tsakiridis, I. G. (2025) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001428 · Cited by 8
First Episode and Recurrent Venous Thromboembolism: Who is Identifiably at Risk?
Liem, T. K., & DeLoughery, T. G. (2008) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2008.05.006 · Cited by 8
Kearon, C. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.06.003 · Cited by 8
Anticoagulant treatment at a specialized outpatient anticoagulant therapy unit, a descriptive study
Ekblom, K., Hultdin, J., Carlberg, B., & STRAND, T. (2005) · Thrombosis Journal · doi:10.1186/1477-9560-3-20 · Cited by 8
“There is still a debate about the benefits and disadvantages of low-dose warfarin treatment after deep venous thrombosis [15-17].”
BackgroundLong-Term Anticoagulation Prophylaxis Following Acute Thromboembolism
Hyers, T. M. (2005) · Disease-a-Month · doi:10.1016/j.disamonth.2005.03.011 · Cited by 8
Ageno, W., Cosmi, B., Ghirarduzzi, A., Santoro, R., Bucherini, E., Poli, D., Prisco, D., Alatri, A., Pengo, V., Galli, L., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23198 · Cited by 8
Long-term Anticoagulant Therapy for Idiopathic Pulmonary Embolism in the Elderly
Haspel, J. A., Bauer, K. A., Goehler, A., & Roberts, D. H. (2008) · CHEST Journal · doi:10.1378/chest.08-1164 · Cited by 8
Self-citationAgnelli, G. (2004) · Drugs · doi:10.2165/00003495-200464001-00007 · Cited by 8
“The use of warfarin, either at low intensity (as in the Prevention of Recurrent Venous Thromboembolism trial) [18] or standard intensity (as in the Extended Low-Intensity Anticoagulation for ThromboEmbolism trial), [19] for secondary prevention of venous thromboembolism has been studied.”
MethodUpdate in the Treatment of Venous Thromboembolism
Garcia, D. A., & Spyropoulos, A. C. (2008) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2008-1047561 · Cited by 8
Scoring Systems for Diagnosis of Acute Venous Thromboembolism
Righini, M., Wells, P. S., & Gal, G. L. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1601332 · Cited by 8
Bergqvist, D. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00298.x · Cited by 8
Ximelagatran: A clinical perspective
Boos, C. J., Hinton, A., & Lip, G. Y. H. (2005) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2005.02.005 · Cited by 9
“09) [64–93].”
BackgroundDiagnosis and Anticoagulant Treatment
Nicolaides, A. N., Fareed, J., Kakkar, A. K., Comerota, A. J., Goldhaber, S. Z., Hull, R., Myers, K., Samama, M. M., Fletcher, J. M., Kalodiki, E., et al. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612474840n · Cited by 7
Self-citationComment et chez qui faut-il surveiller les traitements anticoagulants ?
Smadja, D. M., Gendron, N., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.06.002 · Cited by 7
Kang, H., Lo‐Ciganic, W., DeRemer, C. E., Dietrich, E. A., Huang, P., & Park, H. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2611 · Cited by 7
Nakamura, M., Tamaru, S., Hirooka, S., Hirayama, A., Tsuji, A., Hirata, M., Munemasa, M., Nakagawa, I., Toshima, M., Shimokawa, H., et al. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0158 · Cited by 8
Whinna, H. C., Lesesky, E. B., Monroe, D. M., High, K. A., Larson, P. J., & Church, F. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00796.x · Cited by 7
Coordinated anticoagulation management in a rural setting
Hodge, K., Janus, E. D., Sundararajan, V., Taylor, S. E., Brand, W., Ibrahim, J., & Wolff, A. M. (2008) · PubMed · doi:10.26181/22200253 · Cited by 7
Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism
Bauersachs, R. M. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.05.022 · Cited by 7
“Although the placebo-controlled study demonstrated better efficacy of the low-dose warfarin regimen versus placebo [36], comparison with the standard dose revealed that low-dose warfarin was less effective for the long-term prevention of VTE and was associated with a similar risk of clinically important bleeding event…”
Bauersachs, R. M., & Breddin, H. K. (2004) · Der Internist · doi:10.1007/s00108-004-1161-3 · Cited by 7
Using non-vitamin K oral anticoagulants in specific patient populations: a study of Korean cases
-, I. C. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s204377 · Cited by 7
Venous Thrombosis: Risk Factors and Management
Righini, M., & Bounameaux, H. (2007) · Herz · doi:10.1007/s00059-007-2931-1 · Cited by 7
“5–2) may be useful at least in selected patients at higher risk of bleeding [39, 40].”
Self-citationDiagnosis and Management of Subclavian Vein Thrombosis: Three Case Reports and Review of Literature
Smith, R. A., & Dimitri, S. (2008) · Angiology · doi:10.1177/0003319707305917 · Cited by 7
Siragusa, S., Caramazza, D., & Malato, A. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07578.x · Cited by 7
Venous Thromboembolism Guidebook, Fourth Edition
Gelfand, E. V., Piazza, G., & Goldhaber, S. Z. (2003) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/01.hpc.0000099520.72099.bd · Cited by 7
Self-citationAntidotes to haemorrhage: recombinant factor VIIa
Kessler, C. M. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.03.010 · Cited by 7
Self-citationLow-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly
Pineo, G. F., & Hull, R. D. (2005) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602960501100102 · Cited by 7
“0 was more effective than placebo (42), another study comparing the efficacy and safety of warfarin with an INR of 2.”
BackgroundPrise en charge des affections veineuses chroniques des membres inférieurs
Nicolaides, A. N., Allegra, C., Bergan, J. J., Bradbury, A. W., Cairols, M. A., Carpentier, P., Comerota, A. J., Delis, C., Eklöf, B., Fassiadis, N., et al. (2009) · Journal des Maladies Vasculaires · doi:10.1016/s0398-0499(09)75325-9 · Cited by 7
Santana, A. N. C., Ab’Saber, A. M., Teodoro, W. R., Capelozzi, V. L., & Barbas, C. S. V. (2010) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132010000600009 · Cited by 6
Deep Vein Thrombosis and Pulmonary Embolism
Goldhaber, S. Z. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00016-6 · Cited by 7
Self-citationMars or Venus — Is Sex a Risk Factor for Recurrent Venous Thromboembolism?
Elliott, C. G., & Rubin, L. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048079 · Cited by 7
Self-citationNew Therapeutic Approaches in Pulmonary Embolism
Schellong, S., & Schmidt, B. (2003) · Respiration · doi:10.1159/000075198 · Cited by 7
“presented a randomized controlled follow-up study with the same approach indicating that the group with prolonged secondary prophylaxis experienced a rebound in recurrent events after discontinuation of medication, which annihilated the benefit achieved in the first year of treatment. No data have been published to re…”
ResultInfluentialSecondary Prevention of Venous Thromboembolism
Blondon, M., & Bounameaux, H. (2015) · Circulation · doi:10.1161/circulationaha.115.019310 · Cited by 8
Self-citationFolkerts, K., Broughton, J., Sheikh, U., & Mckaig, S. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1658589 · Cited by 6
Spyropoulos, A. C., & Haire, W. D. (2003) · Journal of Thrombosis and Thrombolysis · doi:10.1023/b:thro.0000011378.16223.e4 · Cited by 6
Sista, A. K. (2014) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2014.02.011 · Cited by 6
Kuntz, J., Cheesman, J. D., & Powers, R. D. (2006) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2006.01.009 · Cited by 6
Update on Pharmacologic Therapy for Pulmonary Embolism
Harikrishnan, P., Palaniswamy, C., & Aronow, W. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413506612 · Cited by 7
The enigmas of the lupus anticoagulant: Mechanisms, diagnosis, and management
Marlar, R. A., & Husain, S. (2008) · Current Rheumatology Reports · doi:10.1007/s11926-008-0013-x · Cited by 6
Khan, F., Kimpton, M., Tritschler, T., Gal, G. L., Hutton, B., Fergusson, D. A., & Rodger, M. A. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1175-5 · Cited by 6
Anti-thrombotic and anti-inflammatory activity of sulodexide compared to aspirin in the rat model
Sohn, S., Kim, T. S., Kim, J., Yoo, S. M., & Jo, W.-M. (2020) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-201043 · Cited by 6
“Warfarin can reduce the risk of venous thromboembolism recurrence, but also has been shown to increase bleeding risk [21].”
Prevention of thrombosis with warfarin, aspirin, and mechanical methods
Merli, G. J. (2005) · Clinical cornerstone · doi:10.1016/s1098-3597(05)80103-6 · Cited by 5
Barriers to the Use of Warfarin: Potential Solutions
McAnulty, J. H. (2004) · Journal of Interventional Cardiac Electrophysiology · doi:10.1023/b:jice.0000011341.67214.2e · Cited by 6
Bleeding and thrombosis in the cancer patient
Zakarija, A., & Kwaan, H. C. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.2.271 · Cited by 6
Schellong, S., Bounameaux, H., & Buller, H. R. (2009) · doi:10.1093/med/9780199566990.003.037 · Cited by 6
Self-citationAgnelli, G. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00812.x · Cited by 5
Protein Z Levels, Protein Z G79A Polymorphism, and Prothrombotic Conditions
Sofi, F., Cesari, F., Gensini, G. F., Abbate, R., & Fedi, S. (2005) · Stroke · doi:10.1161/01.str.0000176583.83769.63 · Cited by 6
Lin, R., Huang, Z., Liu, Y., & Zhou, Y. (2025) · Biosensors · doi:10.3390/bios15030191 · Cited by 5
“…arti fi - cial heart valve replacement surgery [202]. used and treatment of various thrombotic disorders, including deep vein , pulmonary embolism (PE) [200], and thromboembolism prevention [201] atrial fibrillation, and thrombosis risk management following artificial replacement surgery [202].”
aguda, G. D. T. D. L. S. P. L. G. D. L. E. 2. S. E. D. Y. T. D. L. E. P., aguda, R. E. P. L. G. D. L. E. 2. S. E. D. Y. T. D. L. E. P., & Comité de Guías de la, S. E. C. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.11.006 · Cited by 5
Freire, J. L., Lip, G. Y. H., del Blanco, B. G., González, I. F., Mutuberría, M., Alfonso, F., Bueno, H., Cequier, A. R., Prendergast, B., Zueco, J., et al. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.021 · Cited by 5
Quelle est la durée du traitement anticoagulant pour une EP/TVP proximale ?
Couturaud, F., Girard, P., Laporte, S., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.022 · Cited by 5
Benabdellah, A. C., & Zekhnini, K. (2021) · International Conference on Transportation and Smart Technologies (TST) · doi:10.1109/tst52996.2021.00020 · Cited by 5
Li, D., Liu, Y., Song, Y. H., & Wen, A. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2026002 · Cited by 5
Durée optimale du traitement anticoagulant au décours d’une embolie pulmonaire
Couturaud, F. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2011.04.017 · Cited by 5
Optimal duration of anticoagulation in patients with venous thromboembolism.
Prandoni, P., Piovella, C., Spiezia, L., Valle, F. D., & Pesavento, R. (2011) · PubMed Central · Cited by 5
Duration of Anticoagulation for Venous Thromboembolic Events
Smilowitz, N. R., Mega, J. L., & Berger, J. S. (2014) · Circulation · doi:10.1161/circulationaha.114.010456 · Cited by 5
Patterns of Care and Clinical Outcomes in Patients with Cerebral Sinus Venous Thrombosis
Holcombe, A. L., Mohr, N. M., Farooqui, M., Dandapat, S., Dai, B., Zevallos, C. B., Quispe‐Orozco, D., Siddiqui, F. M., & Ortega‐Gutiérrez, S. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.105313 · Cited by 5
MacLehose, R. F., Zakai, N. A., Walker, R. F., Alonso, Á., Adams, T., & Lutsey, P. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12514 · Cited by 5
Liu, Z., Tan, J., Deng, Y.-R., Hua, L., & Guo, T. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120414 · Cited by 7
Orale Antikoagulanzien vom Cumarintyp
Kemkes‐Matthes, B. (2008) · Hämostaseologie · doi:10.1055/s-0037-1617188 · Cited by 5
De, T., Christopher, R., & Nagaraja, D. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.01.037 · Cited by 5
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Tran, H. A., McRae, S. J., & Ginsberg, J. S. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2007.12.006 · Cited by 5
Perrier, A. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2403001 · Cited by 5
The optimal duration of secondary thromboprophylaxis in patients with venous thromboembolism
Kyrle, P. A. (2005) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-004-0135-3 · Cited by 5
Morris, T. A., & Fedullo, P. F. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00051-1 · Cited by 5
Venous Thromboembolism Guidebook
Piazza, G., & Goldhaber, S. Z. (2006) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/01.hpc.0000243629.32681.b6 · Cited by 5
Self-citationIssues in anticoagulant therapy: recent trials start to answer the tough questions.
Jaffer, A. K. (2005) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.72.2.157 · Cited by 5
Anticoagulation in Acute Pulmonary Embolism
Kelly, J., Rudd, A., Hunt, B. J., & Lewis, R. R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1195 · Cited by 5
Metadata
- Authors
- Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., Paulson, R., Wong, T., Bauer, K. A., Schwartz, B. A., Miletich, J. P., Bounameaux, H., & Glynn, R. J.
- Affiliations
- Brigham and Women's Hospital (US)
- National Institutes of Health (US)
- Washington University in St. Louis (US)
- Cleveland Clinic (US)
- University of Vermont (US)
- University of North Carolina at Chapel Hill (US)
- Georgetown University Medical Center (US)
- LDS Hospital (US)
- Altru Health System (US)
- St. Boniface Hospital (CA)
- Beth Israel Deaconess Medical Center (US)
- University Hospital of Geneva (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-10
- Volume
- 348
- Issue
- 15
- Pages
- 1425-1434
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112757583
- Cited by
- 808
- References
- 29
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 13 · 2020: 16 · 2019: 23 · 2018: 16 · 2017: 19 · 2016: 25 · 2015: 24 · 2014: 45 · 2013: 38 · 2012: 44
- FWCI
- 53.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- recurrent venous thromboembolism, long-term anticoagulation, idiopathic venous thromboembolism, major bleeding, inherited thrombophilia, international normalized ratio, benefit-risk balance
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk, Thromboembolism, Warfarin, International Normalized Ratio, Venous Thrombosis, Stroke, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
